about
Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity.Inherited human IRAK-1 deficiency selectively impairs TLR signaling in fibroblastsPossible alternatives to antimicrobial therapies.De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.Autologous human cytomegalovirus-specific cytotoxic T cells as rescue therapy for ulcerative enteritis in primary immunodeficiency.BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy.Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients.Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors.Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.T cell therapy for nasopharyngeal carcinoma.T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children.Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responsesPreemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell TransplantationInfections and Organ TransplantationPosttransplant Soluble B-Cell Activating Factor Kinetics in Pediatric Recipients of First Kidney AllograftPolyomavirus BK-specific immunity after kidney transplantationIntensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a caseProspective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipientsPolyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipientFailure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study
P50
Q37127201-857ABB6B-A583-4DAD-9F4D-E0826D49D913Q37612571-79052F51-BDA5-42FB-8357-D4D73B50D7E3Q38202766-F2963C36-3EBF-4CA2-8E89-4605101A80D8Q38861456-ECDA84B9-A875-4024-A0A5-D3F7F81AF145Q38989164-DD9B1C17-6189-420C-AD26-500DF123BB84Q39122060-CFE828DC-1182-4E91-B9C8-AA46296DE9AFQ40297565-03FCF228-A4AE-4F63-AF00-39203CE1BD2BQ40613236-63D21776-E942-4A72-91B1-D88D79B73A19Q40621628-782379D7-D9D4-4C86-BC8A-F87E1448C2FBQ42273138-CECCD3D1-DDBC-4864-BA45-24D46179F538Q42766336-D1380521-8DE7-48DF-B99E-C0E083411A39Q44267072-F5EC1362-9E0C-4B6E-B759-E3D56663CC5AQ45423535-E24AA9BA-ED2B-4E2F-8901-AAFFE5223590Q45703908-EF2CCCC8-D952-41E9-B7CC-126861F734C8Q51585363-B32C9AA0-DFBC-4C04-B9E3-E42C0AE51263Q51981530-3F7A1473-92D9-4238-B45A-C6284C45C4D6Q56905154-AFC908A7-CB99-4741-88CE-D01B619977F4Q57275302-B5080F74-1B76-42B6-81D8-EBEA2728181EQ57718848-A59E5308-E76A-4BEC-81EE-E76653ADA7D8Q58620392-D5A54E19-1296-48F2-98D6-C5B169F468EDQ80903029-F3210C01-DBAE-42AD-990F-D2D5E1234717Q81073729-C1424302-7EAA-49EC-BD12-085989F888E1Q81379957-E388F8C8-4E41-4265-94E0-B00FE26084F8Q85157571-5CFC960D-D27C-44EF-BBD0-039D8660587CQ90750362-284BBAF6-D2A7-47F5-9AD9-3DF4C0143ED9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sabrina Basso
@ast
Sabrina Basso
@en
Sabrina Basso
@es
Sabrina Basso
@nl
type
label
Sabrina Basso
@ast
Sabrina Basso
@en
Sabrina Basso
@es
Sabrina Basso
@nl
prefLabel
Sabrina Basso
@ast
Sabrina Basso
@en
Sabrina Basso
@es
Sabrina Basso
@nl
P106
P1153
7004060764
P21
P31
P496
0000-0003-2377-815X